Summary by Moomoo AI
Kangfang Biotechnology (Cayman) Limited filed with Hong Kong Trading and Settlement Limited on 5 April 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's shares for the year ended 31 March 2024. The report showed that the company's regulated/registered share capital remained unchanged in March, holding 5,000,000,000 shares with a face value of $0.00001 per share for a total of $50,000. In addition, on 28 March 2024, the Company distributed 24,800,000 new shares under general authorisation at a price of HK$47.65 per share and completed all relevant legal and listing procedures in the same month. In terms of stock options, under the Company's initial public offering post-sale share option plan adopted on June 28, 2022, with no additional share options during the month and the number of deposits remained at 450,000 shares. Changes in other types of securities are not mentioned in the report.